Merrill maintains Forest at buy

Forest Laboratories Inc. was kept at a buy by Merrill Lynch analyst Gregg Gilbert following the conclusion of the Lexapro trial. An opinion from the judge is expected by the end of June. Merrill believes that the judge's rather quick decision, plus the fact that composition of matter patents historically hold up well to challenges, are good signs for Forest. Shares of the New York City pharmaceutical company were unchanged at $44.26 on volume of 2,393,400 shares versus the three-month running average of 2,401,090 shares. (NYSE: FRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.